Clinical Trials Logo

Recurrent Pituitary Adenomas clinical trials

View clinical trials related to Recurrent Pituitary Adenomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT03930771 Terminated - Clinical trials for Recurrent Pituitary Adenomas

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

TMZ-Cap
Start date: May 21, 2019
Phase: Phase 2
Study type: Interventional

This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities. Enrolled patients will receive treatment in 28-day cycles: capecitabine 1500mg/m2 per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14 and oral temozolomide 150 to 200 mg/m2 on days 10 through 14. This will be followed by 14 days off treatment. MRI imaging will be completed after every two cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.